Alcresta Therapeutics, Inc
Alcresta Therapeutics, Inc., based in Waltham, MA, is dedicated to developing enzyme-based products that address fat malabsorption in patients requiring enteral nutrition, particularly those with rare diseases. Their flagship product, RELiZORB, features a patented microbead enzyme technology designed to facilitate fat digestion and absorption in individuals unable to fully benefit from standard enteral formulas.
Serving both children and adults, Alcresta's solutions target conditions such as cystic fibrosis, short bowel syndrome, and pancreatitis. Through clinical trials and a pediatric patient registry, the company aims to enhance the quality of life for patients facing complex nutritional challenges.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.